Home > Inhibitors & Agonists > PI3K/Akt/mTOR
Cat. No. Product name CAS No.
DC7348 3-Methyladenine

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM.

5142-23-4
DC11929 ME-344

A novel mitochondrial and mTOR inhibitor with potent anti-cancer activity, inhibits leukemia cell lines with IC50 of 70-260 nM.

1374524-68-1
DC11968 OSU-03013

A novel potent, orally active 3-phosphoinositide-dependent kinase-1 (PDK-1) with IC50 of 2 uM.

742112-34-1
DC11599 PF-739

A novel potent, pan-AMPK activator with similar potency for all AMPK heterotrimers.

1852452-14-2
DC11631 INCB040093

A novel potent, selective, orally available PI3Kδ inhibitor with IC50 of 31 nM.

1262440-25-4
DC11795 BL-140

A novel specific p110β inhibitor with IC50 of 5.74 nM.

663620-66-4
DC10646 VPS34 inhibitor(Compound 80)

A novel VPS34 inhibitor.

DC11938 IPI-3063

A novel, potent, and selective p110δ PI3K inhibitor with IC50 of 0.1 nM in cell-based assays.

1425043-73-7
DC11656 AMPK-Activator-13

A potent, allosteric, α1-selective small molecule activator of AMPK (EC50=20 nM).

1243184-62-4
DC11866 AZD 3147

A potent, selective dual mTORC1 and mTORC2 inhibitor with enzyme IC50 of 1.5 nM.

1101810-02-9
DC11841 LAS191954

A potent, selective, orally bioavailable PI3Kδ inhibitor with IC50 of 2.6 nM.

1403947-26-1
DC7538 A66

A66 is a potent and specific p110α inhibitor with IC50 of 32 nM, >100 fold selectivity for p110α over other class-I PI3K isoforms.

1166227-08-2
DC5163 A-674563

A-674563 is a potent, orally available Akt1 inhibitor with an IC50 value of 11nM. Also displays activity against PKA and CDK2 with IC50 values of 16nM and 46nM respectively.

552325-73-2
DC7045 A-769662

A-769662 is a potent, reversible AMPK activator with EC50 of 0.8 μM, little effect on GPPase/FBPase activity.

844499-71-4
DC7047 AICAR (Acadesine)

Acadesine results in accumulation of ZMP, which mimics the stimulating effect of AMP on AMPK and AMPK kinase. Phase 3.

2627-69-2
DC8760 Acalisib

Acalisib (GS-9820) is a potent and selective inhibitor of PI3Kδ with IC50 value of 12.7 nM.

870281-34-8
DC7994 Afuresertib HCl

Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM).

1047645-82-8
DC8411 Afuresertib

Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

1047644-62-1
DC8458 Akt Inhibitor VIII

Akt Inhibitor VIII is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit Akt1, Akt2, and Akt3 activity (IC50 = 58 nM, 210 nM, and 2.12 μM; respectively).

612847-09-3
DC8695 Akt1 and Akt2-IN-1

Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 (IC50 = 3.5 nM) and Akt2 (IC50 = 42 nM), with potent and balanced activity.

893422-47-4
DC8618 AMG-319

AMG 319 is an investigational, highly selective, small molecule inhibitor of PI3Kδ that blocks B cell proliferation following BCR stimulation both in vitro and in vivo, inhibits basal AKT phosphorylation, and inhibits proliferation in lymphoid tumor cells

1608125-21-8
DC11130 AMPK activator 991

AMPK activator 991 is an allosteric AMPK activator, activates non-phosphorylated Thr172 AMPK in vitro binds to α1β1γ1 and α2β1γ1 with Kd of 0.13 and 0.17 uM, respectively..

1219739-95-3
Page 1 / Total 7 FirstPrevNextLastGoto